(NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor ...

Inc. (NASDAQ:ETNB – Get Free Report)’s share price dropped 3.7% during trading on Tuesday . The company traded as low as $7.50 and last traded at $7.50. Approximately 101,562 shares were traded during ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...

On Friday, 89bio Inc (ETNB) stock saw a modest uptick, ending the day at $7.94 which represents a slight increase of $0.91 or 12.94% from the prior close of $7.03. The stock opened at $7.03 and ...

89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate ...

MASH is a culmination of steatosis, inflammation, and fibrosis, and is also associated with comorbidities such as obesity and ...

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company” or "89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

89Bio, Inc. (NASDAQ:ETNB), with a market capitalization of $925 million and current share price of $7.88, is a biopharmaceutical company focused on developing therapies for liver and cardio-metabolic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpointsSAN FRANCISCO, Nov. 15, 2024 ...

89bio Inc . (NASDAQ:ETNB), a clinical-stage biopharmaceutical company valued at $937 million, is navigating the complex landscape of metabolic and liver diseases with its lead candidate, pegozafermin.